Skip to content
Friday 14 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,766.27
-0.06%
DAX
26,491.68
+0.73%
CAC 40
8,658.93
+0.10%
STOXX 50
6,564.18
+0.29%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE
Friday 08 January 2021 12:14 pm  |  Updated:  Friday 08 January 2021 1:45 pm

Moderna’s Covid vaccine gets green light from UK

By: Poppy Wood

Add as a preferred source on Google

The UK’s medicines regulatory body has authorised the Moderna vaccine for emergency use, the company has announced, in a major boost to the nation’s vaccination efforts.

The US-made drug becomes the third coronavirus vaccine granted approval for use by the Medicines & Healthcare products Regulatory Agency (MHRA) in Britain, as ministers ramp up plans to vaccinate more than 13m people by mid-February.

The government has ordered an additional 10m doses of the jab, taking the UK’s total order to 17m.

The drug proved 94 per cent effective in protecting against coronavirus in clinical trials.

The vaccine’s approval comes as an unexpected boost for the country’s ambitious vaccination programme, with the jab previously anticipated to be delivered much later this year. 

MHRA chief executive Dr June Raine said: “Today’s approval brings more encouraging news to the public and the healthcare sector. Having a third Covid-19 vaccine approved for supply following a robust and thorough assessment of all the available data is an important goal to have achieved and I am proud that the agency has helped to make this a reality.”

The US granted emergency authorisation for the Moderna vaccine in mid-December, with the EU following suit yesterday.

The government has spread orders across seven potential vaccines that use a variety of methods, stressing that vaccination across the population will not be achieved by a “one size fits all method”.

Read more

ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer

Around 1.5m people have already received at least one dose of either the Astrazeneca or Pfizer vaccine, including almost a quarter of all over-80s in England.

However, the Moderna vaccine will not be available for use straight away, with the first doses not expected to arrive until the spring.

The Prime Minister earlier this week said wide scale vaccine roll-out would require the combined efforts of the NHS and the Armed Forces as the government works “absolutely flat out” to vaccinate the nation before lockdown restrictions are lifted.

Professor Chris Whitty, England’s chief medical officer, said that the vaccine timetable was “realistic but not easy”.

“The NHS is going to have to use multiple channels to get this out, but they are very determined to do this. But that does not make it easy,” he said.

Nadhim Zahawi, the UK’s vaccine tsar yesterday announced that community pharmacy networks will be “very much involved” in plans to vaccinate the most vulnerable members of the population over the next seven weeks.

Current government plans will see vaccines given to GPs to be rolled out to the public, then national vaccination centres, and then distributed across local pharmacies, Zahawi announced.

“The NHS has a very clear plan and I’m confident that we can meet it,” he said, adding that it would require a “Herculean effort” to roll out the jab by mid-February.

Read more

Tenpoint Therapeutics Announces United Kingdom Submission of Marketing Authorization Application to the Medicines and Healthcare Products Regulatory Agency (MHRA) for the Treatment of Blurry Close-Up Vision (Presbyopia) in Adults

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business
  • Morning Wire Content

Related Topics

  • Coronavirus
  • Re-lockdown
  • Vaccine

Trending Articles

  • Revolut takes flight with launch of new airport lounges

  • Grandparents fund university degrees to avoid inheritance tax net

  • It’s not just Jason Arday, most of sociology is a scam

  • IT consultant ordered to pay £50,000 after being accused of stealing Soho House members’ personal details

  • Brompton Bicycle sues former adviser for ‘professional negligence’

More from Morning Wire

  • ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer

    Business Wire
  • Tenpoint Therapeutics Announces United Kingdom Submission of Marketing Authorization Application to the Medicines and Healthcare Products Regulatory Agency (MHRA) for the Treatment of Blurry Close-Up Vision (Presbyopia) in Adults

    Business Wire
  • Clinigen Appoints Greg Skalicky as Chief Executive Officer

    Business Wire
  • Patent cliff fuels Novartis’ $1.5bn swoop for London biotech

    Healthcare
    Hikma produces generic drugs
  • Curaleaf Launches Free CPD-Accredited Platform to Close Medical Cannabis Training Gap for UK Healthcare Professionals

    Business Wire
  • Verdiva Bio Appoints Cardiometabolic Leader Steve Marso as Chief Medical Officer

    Business Wire
  • ICON announces multi-year collaboration with Anthropic to bring frontier AI to clinical trials

    Business Wire
  • Alkermes to Report Second Quarter Financial Results on July 28, 2026

    Business Wire
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook